Recurrent loss of heterozygosity in pancreatic neuroendocrine tumors Journal Article


Authors: Parilla, M.; Chapel, D.; Hechtman, J. F.; Wanjari, P.; El Jabbour, T.; Sharma, A.; Ritterhouse, L.; Segal, J.; Vanderbilt, C.; Klimstra, D. S.; Setia, N.; Tang, L.
Article Title: Recurrent loss of heterozygosity in pancreatic neuroendocrine tumors
Abstract: Chromosomal aneuploidies are prognostic markers across a wide variety of tumor types, and recent literature suggests that pancreatic neuroendocrine tumors are no different. In this study 214 patients with grade 1, 2, or 3 pancreatic neuroendocrine tumors had their tissue examined for chromosomal copy number alterations using next-generation sequencing. Univariate and multivariate statistical analyses were performed with all-cause mortality and disease-specific mortality as the end comparators. As such, the cohort stratified into 3 different clinically relevant chromosomal subgroups: an indolent subgroup characterized by loss of chromosome 11 in relative isolation, an aggressive subgroup characterized by losses of chromosomes 1, 2, 3, 6, 10, 11, 16, and 22 and with no loss of chromosomes 4, 5, 7, 12, 14, 17, 19, and 20, and finally a heterogeneous third group with a subset of cases that behave even more aggressively than the aforementioned.
Keywords: heterozygosity; chromosomes; instability; monosomy; pancreatic neuroendocrine tumor; daxx; atrx; next-generation sequencing; loss of; men1
Journal Title: American Journal of Surgical Pathology
Volume: 46
Issue: 6
ISSN: 0147-5185
Publisher: Lippincott Williams & Wilkins  
Date Published: 2022-06-01
Start Page: 823
End Page: 831
Language: English
ACCESSION: WOS:000794948700011
DOI: 10.1097/pas.0000000000001860
PROVIDER: wos
PMCID: PMC9106831
PUBMED: 35125451
Notes: Article -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David S Klimstra
    978 Klimstra
  2. Laura Hong Tang
    447 Tang
  3. Jaclyn Frances Hechtman
    212 Hechtman